Being prescribed a new treatment for chronic myeloid leukemia (CML) can raise practical questions. Why has olverembatinib been chosen? What is the treatment intended to achieve? How will the response be assessed? And if the medicine is not routinely available in India, what may be involved in accessing it?
This blog explains the role of olverembatinib in CML, what patients may expect from treatment and monitoring, and some of the regulatory considerations involved in accessing the medicine in India.
What Is Olverembatinib?
Olverembatinib, also known as HQP1351, is a third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI).
As of August 2026, olverembatinib is approved and commercially available in China for certain adults with CML, including:
- CML in chronic phase (CML-CP) or accelerated phase (CML-AP) with the T315I mutation; and
- CML-CP that is resistant and/or intolerant to first- and second-generation TKIs.
The medicine is being evaluated in additional treatment settings through global clinical development programs. The global Phase III POLARIS-2 study is evaluating olverembatinib in previously treated CML-CP, including patients with and without T315I.
Importantly, approval in one country does not automatically mean that a medicine is approved or routinely marketed in another country.
Why Olverembatinib May Be the Next Step in CML Treatment
TKIs that target BCR-ABL1 are an important part of CML treatment. However, treatment may not remain effective or tolerable for every person. Resistance can develop, or treatment-related effects may make continued use of a particular TKI difficult.
In these circumstances, the treating physician may reassess the patient’s disease, previous treatments, response, mutation findings where relevant, tolerability and available treatment options.
Olverembatinib has been developed for specific CML treatment settings involving resistance or intolerance to previous TKIs. Its approved indications in China include adults with T315I-mutated CML-CP or CML-AP and adults with CML-CP that is resistant and/or intolerant to first- and second-generation TKIs.
This indication does not mean that olverembatinib is appropriate for every person with CML. The choice of treatment remains a clinical decision based on the individual’s circumstances.
Understanding the Treatment Challenge Behind CML Resistance
When CML does not respond adequately to a TKI, this may be described as treatment resistance. Intolerance is different: it refers to a situation in which treatment-related effects make continued treatment difficult or unsuitable.
One mechanism associated with TKI resistance involves changes, or mutations, in the BCR-ABL1 kinase domain. Such mutations can affect how the BCR-ABL1 protein interacts with particular TKIs and may therefore be relevant when subsequent treatment options are evaluated.
Olverembatinib is designed to inhibit BCR-ABL1, including mutant forms of the kinase associated with treatment resistance. Its clinical development has included patients with CML who had previously received multiple TKIs.
When the T315I Mutation Changes the Treatment Conversation
The T315I mutation is a change in the BCR-ABL1 kinase domain that can affect the activity of several BCR-ABL1-targeted TKIs.
When CML does not respond as expected to previous treatment, mutation testing may provide information that helps the treating physician evaluate possible mechanisms of resistance and consider appropriate treatment strategies.
The clinical relevance of T315I is reflected in olverembatinib’s China-approved indication, which includes adults with CML-CP or CML-AP carrying T315I mutations.
However, the presence of T315I alone does not determine which treatment an individual should receive. The physician considers the mutation together with the patient’s disease phase, previous treatment, response, tolerability and other relevant clinical information.
What Olverembatinib Is Intended to Help Achieve
The aim of CML treatment is to reduce the burden of disease and achieve an appropriate treatment response while managing the disease over time.
Clinical research has reported cytogenetic and molecular responses with olverembatinib in previously treated CML. In a phase 1b randomized clinical trial involving adults with previously treated CML and Philadelphia chromosome-positive acute lymphoblastic leukemia, complete cytogenetic response was observed in 31 of 51 evaluable patients with CML-CP (61%), while major molecular response was observed in 25 of 59 evaluable patients with CML-CP (42%).
These figures describe outcomes observed in a particular clinical-study population. They should not be interpreted as a prediction of the response an individual patient will experience. The response to treatment can vary according to disease characteristics, previous therapy and other clinical factors.
The Treatment Responses Doctors Look For
CML response can be assessed at different levels.
A hematologic response considers blood counts and clinical findings associated with the disease. A cytogenetic response evaluates the proportion of examined cells in which the Philadelphia chromosome is detected. A molecular response evaluates the level of BCR-ABL1 transcript measured through molecular testing.
These assessments provide different information about the depth of response. The treating team determines which assessments are appropriate for the individual patient and how frequently they should be performed.
Following CML Response Throughout Treatment
Follow-up may include blood counts, BCR-ABL1 molecular testing, clinical assessments and other investigations when medically appropriate.
BCR-ABL1 molecular testing can help track changes in the BCR-ABL1 transcript level over time. Results are interpreted in the context of previous measurements, treatment history and other relevant clinical findings.
A single test result does not necessarily determine whether treatment should be continued or changed. The treating physician evaluates the overall pattern of response and the patient’s clinical condition when making treatment decisions.
Taking Olverembatinib as Part of an Ongoing Treatment Plan
Olverembatinib should be taken according to the prescription and instructions provided by the treating physician.
The appropriate strength, dosing schedule, treatment duration and any dose adjustments depend on the applicable product information and the patient’s clinical circumstances. Patients should not independently change their dose, stop treatment or restart treatment without consulting their treating team.
Because dosing can depend on the specific approved product, indication and clinical circumstances, this article does not provide an individual dosing recommendation. Patients should follow the prescribing information applicable to their product and the instructions provided by their physician.
Side Effects, Monitoring and Staying on Treatment
Olverembatinib, like other anticancer treatments, can cause treatment-related adverse effects. In the published phase 1b study, 60 of 80 participants (75%) experienced at least one treatment-related adverse event, while 32 (40%) experienced a grade 3 or higher treatment-related adverse event. Frequently reported treatment-emergent adverse events included elevated blood creatine phosphokinase and thrombocytopenia, as well as nausea, fatigue, and increases in alanine or aspartate aminotransferase levels.
These study results describe the participants enrolled in that trial and do not establish that an individual patient will experience the same effects or frequency of effects.
Depending on the patient’s clinical circumstances, monitoring may include blood tests and other assessments to evaluate treatment response and tolerability. New, persistent or concerning symptoms should be discussed promptly with the treating team rather than being self-assessed as treatment-related or unrelated.
When Treatment Needs to Be Reassessed
Treatment may need to be reassessed if the disease does not respond adequately, if the response changes, or if treatment-related effects affect the ability to continue therapy.
The appropriate next step depends on the individual situation. The physician may consider response assessments, previous treatment exposure, mutation findings, tolerability and other clinical information before deciding whether the existing treatment strategy remains appropriate.
Patients should not discontinue or modify treatment independently because of a laboratory result, symptom or perceived lack of improvement.
Olverembatinib Availability Beyond China
Olverembatinib’s regulatory status differs between countries. As of March 2026, Ascentage Pharma identifies olverembatinib as a product approved in China for the CML indications described above. The company also reports ongoing global registrational Phase III studies evaluating olverembatinib in additional treatment settings, including previously treated CML-CP with or without T315I.
Therefore, olverembatinib availability in another country should not be assumed simply because the medicine is approved and commercially supplied in China. Marketing authorization and commercial availability are determined by the regulatory framework of each jurisdiction.
For those researching Olverembatinib in India, the relevant question may therefore be whether the applicable regulatory requirements permit an individual import in their particular circumstances.
Finding a Path to Olverembatinib Access in India
CDSCO provides information and application facilities for the personal-use import of certain drugs, subject to applicable requirements, including Form 12A and Form 12B.
The CDSCO procedure states that an application in Form 12A is accompanied by a prescription from a registered medical practitioner, with the prescription specifying the drug requirements. The current CDSCO application system also requests information about the patient, drug, quantity, importing country and prescribing doctor, together with the prescription and other specified documentation.
Whether this process is applicable to a particular patient and proposed import depends on the circumstances and the requirements of the competent authority.
Importantly, an individual import permission should not be described as Indian marketing authorization for olverembatinib. These are separate regulatory matters.
Patients considering Olverembatinib access in India should therefore discuss the proposed treatment with their treating physician and follow the applicable CDSCO and import requirements before making arrangements.
Preparing the Documentation for Individual Import
Documentation requirements can depend on the applicable procedure and the circumstances of the proposed import.
Under the CDSCO personal-use procedure, the prescription should identify the drug requirements, and the Form 12A process requires a prescription from a registered medical practitioner. The current online application also includes patient identification information, drug details, quantity, importing country and prescribing-doctor information.
Additional medical or identification documents may be relevant depending on the application and the requirements communicated by the competent authority.
Because regulatory procedures can be updated, patients should verify the current requirements through CDSCO or the relevant authority before preparing an import.
Planning Ahead for Continued Olverembatinib Treatment
For someone receiving ongoing treatment, access may involve more than arranging a single supply. Keeping the current prescription, relevant medical records, treatment details and applicable regulatory documentation organized can help when future supplies need to be considered.
Patients should discuss anticipated treatment requirements with their treating physician before their existing supply is exhausted, particularly where an individual import process may involve documentation or regulatory steps.
For people researching olverembatinib price or olverembatinib cost, the amount payable can vary according to factors such as the specific product and source, prescribed quantity, applicable import requirements and logistics. A price quoted for one supply should therefore not be assumed to represent a universal or total treatment cost.
Patients looking to buy olverembatinib in India can contact 24/7QualityMeds at +91 9967979080 for assistance with availability and access.
